本文選題：Technivie + 慢性丙型肝炎��； 參考：《國(guó)際藥學(xué)研究雜志》2015年05期

【摘要】：正Technivie是翁比他韋(ombitasvir)、帕利普韋(paritaprevir)及利托那韋(ritonavir)固定劑量組合片劑,前者為HCV NS5A抑制劑,中間為HCV NS3/4A蛋白酶抑制劑,后者為CYP3A抑制劑。其與利巴韋林聯(lián)合,專用于治療無(wú)肝硬化的基因型4慢性丙型肝炎病毒(HCV)感染。推薦劑量是每日早餐時(shí)口服1次,2片/次,持
[Abstract]:Positive Technivie is a fixed dose combination tablet of ombitasvirr, paritaprevirr and ritonavir.The former is HCV NS5A inhibitor, the middle is HCV NS3 / 4A protease inhibitor, and the latter is CYP3A inhibitor. It is combined with ribavirin for the treatment of chronic hepatitis C virus (HCV) infection without cirrhosis. The recommended dose is once a day for breakfast and 2 tablets per day.
【分類號(hào)】：R978.7
，

本文編號(hào)：2046463